Recovery & Tissue Repair Preliminary evidence

BPC-157 + TB-500

For: Tissue repair

In plain language

A common recovery pairing of two repair peptides with different reported mechanisms. BPC-157 is studied for tendon, gut, and wound healing, while TB-500 is studied for cell migration and blood-vessel growth. Almost all of the evidence is from animals, and the blend itself is untested in people.

Components

Why these together

The rationale is mechanism diversity. BPC-157 is associated with angiogenesis and gut-lining protection, and TB-500 is associated with actin-driven cell migration and reduced scarring. In theory the two cover different parts of the repair process, which is why they are often paired in recovery research.

Evidence summary

Each peptide has a body of animal work but little or no controlled human evidence. The combination has not been tested in well-designed human trials, so any synergy is hypothetical.

Both components are animal-stage; the combination has essentially no human data

Reported safety

Human safety is not established for either peptide or the combination. TB-500 is prohibited in competitive sport. Reported tolerability comes from animal studies, which do not establish human safety.

Regulatory statusNeither is FDA-approved; research use only
Sport statusTB-500 is prohibited by WADA
Human dataNo controlled human trials of the combination

Frequently asked

Do BPC-157 and TB-500 do the same thing?

No. They are both studied for repair, but their reported mechanisms differ, which is the usual reason given for combining them.

Is there human evidence for this stack?

Essentially none. The evidence is preclinical, so this blend carries a preliminary evidence tier.

Other blends